Seres TherapeuticsMCRB
MCRB
About: Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
Employees: 103
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
238% more call options, than puts
Call options by funds: $132K | Put options by funds: $39K
13% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 15
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
1.67% less ownership
Funds ownership: 36.94% [Q4 2024] → 35.28% (-1.67%) [Q1 2025]
7% less funds holding
Funds holding: 69 [Q4 2024] → 64 (-5) [Q1 2025]
18% less capital invested
Capital invested by funds: $52.5M [Q4 2024] → $43.1M (-$9.4M) [Q1 2025]
45% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 11
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$6
20%
downside
Avg. target
$6
20%
downside
High target
$6
20%
downside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
Chardan Capital Keay Nakae | 20%downside $6 | Neutral Downgraded | 8 May 2025 |
Financial journalist opinion
Based on 3 articles about MCRB published over the past 30 days
Neutral
GlobeNewsWire
2 weeks ago
Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting
Results highlight potential role of SER-155 in promoting peripheral T-cell recovery and immune reconstitution to support favorable outcomes post allogeneic hematopoietic stem cell transplant (allo-HSCT) Results highlight potential role of SER-155 in promoting peripheral T-cell recovery and immune reconstitution to support favorable outcomes post allogeneic hematopoietic stem cell transplant (allo-HSCT)
Positive
Zacks Investment Research
3 weeks ago
Seres Therapeutics (MCRB) Upgraded to Buy: What Does It Mean for the Stock?
Seres Therapeutics (MCRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Positive
Zacks Investment Research
4 weeks ago
Wall Street Analysts Believe Seres Therapeutics (MCRB) Could Rally 713.09%: Here's is How to Trade
The mean of analysts' price targets for Seres Therapeutics (MCRB) points to a 713.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Neutral
Seeking Alpha
1 month ago
Seres Therapeutics, Inc. (MCRB) Q1 2025 Earnings Call Transcript
Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q1 2025 Earnings Call May 7, 2025 8:30 AM ET Company Participants Carlo Tanzi - Investor Relations Eric Shaff - President and Chief Executive Officer Marella Thorell - Chief Financial Officer Matthew Henn - Chief Scientific Officer Terri Young - Chief Commercial and Strategy Officer Dennis Walling - Senior Vice President, Clinical Development Conference Call Participants Caroline Pötsch-Hennig - JPMorgan Joseph Thome - TD Cowen John Newman - Canaccord Operator Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator today.
Neutral
GlobeNewsWire
1 month ago
Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
In line with recent FDA feedback, Seres expects to submit a Phase 2 study protocol to FDA in the coming weeks for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) for the treatment of hematological malignancies SER-155 Phase 1b placebo-controlled study exploratory translational biomarker data reinforce intended mechanisms of action, consistent with clinical results that showed a significant reduction (77% relative risk reduction) in BSIs, and support broader potential for Seres' live biotherapeutics to address inflammatory and immune diseases Seres advancing SER-155 strategic partnership discussions in support of further development in allo-HSCT and potential expansion into other target populations Conference call at 8:30 a.m. ET today CAMBRIDGE, Mass.
Neutral
GlobeNewsWire
1 month ago
Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases
CAMBRIDGE, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that it will present three related posters at the upcoming 2025 Digestive Disease Week (DDW) Conference being held May 3-6, 2025, in San Diego, CA.
Neutral
GlobeNewsWire
1 month ago
Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025
CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on May 7, 2025 at 8:30 a.m. ET to discuss first quarter 2025 financial results and provide business updates.
Positive
Zacks Investment Research
1 month ago
Down -48.7% in 4 Weeks, Here's Why Seres Therapeutics (MCRB) Looks Ripe for a Turnaround
Seres Therapeutics (MCRB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Neutral
24/7 Wall Street
1 month ago
Stock Splits Matter: Here's What's Coming Up Soon
While stock splits are not as common as they were a couple of decades ago, a number of notable ones have happened in the past year.
Neutral
Seeking Alpha
3 months ago
Seres Therapeutics, Inc. (MCRB) Q4 2024 Earnings Call Transcript
Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q4 2024 Earnings Conference Call March 13, 2025 8:30 AM ET Company Participants Carlo Tanzi - Kendall Investor Relations Eric Shaff - President and Chief Executive Officer Lisa von Moltke - Executive Vice President and Chief Medical Officer Matthew Henn - Executive Vice President and Chief Scientific Officer Terri Young - Executive Vice President, Chief Commercial and Strategy Officer Marella Thorell - Executive Vice President and Chief Financial Officer Chris McChalicher - Senior Vice President, Manufacturing, Quality and Process Development Conference Call Participants Joseph Thome - TD Cowen Caroline Pocher - JPMorgan Edward Tenthoff - Piper Sandler John Newman - Canaccord Genuity Operator Thank you for standing by. My name is Kate, and I will be your conference operator today.
Charts implemented using Lightweight Charts™